Tuberculosis in Patients with Primary Myelofibrosis During Ruxolitinib Therapy: Case Series and Literature Review
Yizhou Peng,1 Li Meng,1 Xuemei Hu,2 Zhiqiang Han,3 Zhenya Hong1 1Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, People’s Republic of China; 2Department of Radiology, Tongji Hospital, Tongji Medical College, Hu...
Main Authors: | Peng Y, Meng L, Hu X, Han Z, Hong Z |
---|---|
Format: | Article |
Language: | English |
Published: |
Dove Medical Press
2020-09-01
|
Series: | Infection and Drug Resistance |
Subjects: | |
Online Access: | https://www.dovepress.com/tuberculosis-in-patients-with-primary-myelofibrosis-during-ruxolitinib-peer-reviewed-article-IDR |
Similar Items
-
Reactivation of tuberculosis following ruxolitinib therapy for primary myelofibrosis: Case series and literature review
by: Farhan Khalid, et al.
Published: (2021-09-01) -
Efficacy of ruxolitinib retreatment in a patient with high-risk myelofibrosis using the international prognostic scoring system
by: Vincenzo Accurso, et al.
Published: (2019-03-01) -
Beyond Ruxolitinib: Fedratinib and Other Emergent Treatment Options for Myelofibrosis
by: Bewersdorf JP, et al.
Published: (2019-12-01) -
Combination therapy with ruxolitinib plus low-dose cytarabine or mercaptopurine in patients with blast-phase myelofibrosis
by: M. S. Fominykh, et al.
Published: (2016-08-01) -
Ruxolitinib for treatment of polycythemia vera and myelofibrosis in patients after liver transplantation
by: Leona Dold, et al.
Published: (2021-09-01)